Accessibility Information

Users of assistive technologies such as screen readers should use the following link to activate Accessibility Mode before continuing: Learn more and Activate accessibility mode.

Highly Potent Cancer Nanotherapeutics

Solicitation Number: S10-140
Agency: Department of Health and Human Services
Office: National Institutes of Health
Location: National Cancer Institute
  • Print

Note:

There have been modifications to this notice. You are currently viewing the original synopsis. To view the most recent modification/amendment, click here
:
S10-140
:
Combined Synopsis/Solicitation
:
Added: Apr 01, 2010 10:22 am
E-mail questions in writing to desantisma@mail.nih.gov by 3:00 pm (ET) by April 12, 2010.

The purpose of this subcontract is to identify and evaluate the potential of candidate nanotechnologies to significantly improve the therapeutic index, bioavailability, solubility, and/or pharmacokinetics of otherwise failed anti-cancer agents. Specifically, this subcontract is intended to fund nanotechnology delivery systems which will allow anti-cancer drugs which could not otherwise be delivered in free form due to their excessive toxicity, poor oral bioavailability, poor solubility in biological fluids, inappropriate pharmacokinetics, and lack of efficacy within a tolerable dose range to be re-examined as potential therapies for cancer treatment. The purpose of this subcontract is NOT to fund basic research on nanoplatform development nor is it intended to fund the new synthesis approach to failed anti-cancer compounds.

If the drug can currently be administered to humans in free form and the drug-nanoparticle construct provides only an incremental improvement over the free drug, then the drug-nanoparticle construct is not of interest to NCI and SAIC-Frederick. If, however, the drug-nanoparticle construct results in a significant improvement in properties over the free drug, then NCI and SAIC-Frederick would be interested in the drug-nanoparticle construct. If the drug can not currently be administered to humans in free form and the drug-nanoparticle construct mitigates the unacceptable properties of the drug allowing the drug to be re-evaluated as an anti-cancer agent, then NCI and SAIC-Frederick would be very interested in the drug-nanoparticle construct.

Please consult the list of document viewers if you cannot open a file.

S10-140

Type:
Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Label:
S10-140
Posted Date:
April 1, 2010
Description: Highly Potent Cancer Nanotherapeutics
:
Bldg 427, Room 12
Frederick, Maryland 21702
:
Subcontractor's site

United States
:
Matt DeSantis,
Senior Subcontracts Specialist
Phone: 301/228-4002
Fax: 301/228-4037
:
Shannon B Jackson,
Supervisor, Research Subcontracts
Phone: 301-228-4022
Fax: 301-228-4037